ImmuPharma plc, a specialist drug discovery and development company, has selected Thermo Fisher Scientific as the contract ...

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon.

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported ...

New research being presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) ...

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of ...

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers ...

Mounjaro is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with the active ingredient ...

GIP-based and weekly injectable therapies for type-2 diabetes and obesity, plus lifestyle advice and side effects.

Two of those options are brand-name Mounjaro and medications with the active ingredient semaglutide. Keep reading to learn ...

Published in BMJ Open, the study, Association between GLP-1 receptor agonists and alcohol-related hospitalizations among adults with alcohol use disorder: A multi-target trial emulation study, ...

Researchers from Truveta, Johns Hopkins Bloomberg School of Public Health, Duke University, Providence, and collaborating ...

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that ...